Home
PSNL
PSNL News

Latest Personalis Inc. (PSNL) News on September 18, 2025

TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape

Zacks

6 days ago

TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape

MT Newswires

7 days ago

Personalis Launches Breast Cancer Study with Yale Cancer Center

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Business Wire

7 days ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

The 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394%

Simply Wall St.

3 months ago

The 13% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 394%

Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?

Zacks

3 months ago

Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?

Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Business Wire

3 months ago

Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

MT Newswires

3 months ago

Personalis Says Studies Show NeXT Personal Test Could Identify Relapse Risk in Breast Cancer Patients

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Business Wire

3 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

GOBankingRates

4 months ago

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

3 International Vacations That Are Cheaper Than an iPhone

GOBankingRates

4 months ago

3 International Vacations That Are Cheaper Than an iPhone

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

GOBankingRates

4 months ago

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

This week in Trumponomics: Too bad TACO isn’t true

Yahoo Finance

4 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

The Guardian

4 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Yahoo Finance Video

4 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Benzinga

4 months ago

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Reuters

4 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

Business Wire

4 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

MT Newswires

4 months ago

Guggenheim Initiates Personalis at Buy With $6 Price Target

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

Business Wire

4 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth

Simply Wall St.

4 months ago

Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth

Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com

4 months ago

Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis Reports First Quarter 2025 Financial Results

Business Wire

4 months ago

Personalis Reports First Quarter 2025 Financial Results

Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To Expect

GuruFocus.com

4 months ago

Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To Expect

Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Business Wire

5 months ago

Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires?

Insider Monkey

5 months ago

Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires?

Personalis to Announce First Quarter 2025 Financial Results

Business Wire

5 months ago

Personalis to Announce First Quarter 2025 Financial Results

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Business Wire

5 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

Investor's Business Daily

5 months ago

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

With 33% stake, Personalis, Inc. (NASDAQ:PSNL) seems to have captured institutional investors' interest

Simply Wall St.

5 months ago

With 33% stake, Personalis, Inc. (NASDAQ:PSNL) seems to have captured institutional investors' interest

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Business Wire

6 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

MT Newswires

6 months ago

Craig Hallum Initiates Coverage on Personalis With Buy Rating, $8 Price Target

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Business Wire

7 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Personalis Full Year 2024 Earnings: Beats Expectations

Personalis Inc (PSNL) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

GuruFocus.com

7 months ago

Personalis Inc (PSNL) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates

Zacks

7 months ago

Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

7 months ago

Personalis: Q4 Earnings Snapshot

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire

7 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Personalis Inc (PSNL) Q4 2024 Earnings Report Preview: What To Look For

GuruFocus.com

7 months ago

Personalis Inc (PSNL) Q4 2024 Earnings Report Preview: What To Look For

Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

7 months ago

Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Business Wire

7 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Business Wire

7 months ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Business Wire

8 months ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Personalis (PSNL) Upgraded to Buy: Here's Why

Zacks

8 months ago

Personalis (PSNL) Upgraded to Buy: Here's Why

Researchers find ctDNA test predicts lung cancer outcomes in study

Medical Device Network

8 months ago

Researchers find ctDNA test predicts lung cancer outcomes in study

MT Newswires

8 months ago

Personalis Says Study Shows NeXT Personal Test's 'High Sensitivity' for Lung Cancer Detection

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Business Wire

8 months ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

MT Newswires

8 months ago

Personalis Reports Lower Preliminary Revenue for Q4

Business Wire

8 months ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159%

Simply Wall St.

9 months ago

The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159%

Personalis price target raised to $8 from $7 at BTIG

TipRanks

9 months ago

Personalis price target raised to $8 from $7 at BTIG

MT Newswires

9 months ago

Personalis Rallies Following $50 Million Investment from Merck, Extended Agreement With Moderna

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Business Wire

9 months ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma

Insider Monkey

9 months ago

Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma

MT Newswires

9 months ago

Personalis, Tempus AI Expand Collaboration to Biopharma Industry

Personalis and Tempus Expand Collaboration to Biopharma

Business Wire

9 months ago

Personalis and Tempus Expand Collaboration to Biopharma

Personalis to Participate at Upcoming Investor Conferences

Business Wire

10 months ago

Personalis to Participate at Upcoming Investor Conferences

Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn Situation

Simply Wall St.

10 months ago

Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn Situation

Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ...

GuruFocus.com

10 months ago

Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ...

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

10 months ago

Personalis: Q3 Earnings Snapshot

Business Wire

10 months ago

Personalis Reports Third Quarter 2024 Financial Results

Business Wire

10 months ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Personalis Inc (PSNL) Q3 2024 Earnings Report Preview: What To Expect

GuruFocus.com

10 months ago

Personalis Inc (PSNL) Q3 2024 Earnings Report Preview: What To Expect

Personalis to Announce Third Quarter 2024 Financial Results

Business Wire

a year ago

Personalis to Announce Third Quarter 2024 Financial Results

MT Newswires

a year ago

Personalis Awarded New Task Order Under US Department of Veterans Affairs Contract

Personalis, Inc. (NASDAQ:PSNL) has caught the attention of institutional investors who hold a sizeable 38% stake

Simply Wall St.

a year ago

Personalis, Inc. (NASDAQ:PSNL) has caught the attention of institutional investors who hold a sizeable 38% stake

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Business Wire

a year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Business Wire

a year ago

Personalis to Participate at Upcoming Investor Conferences

Why Tempus AI Stock Skyrocketed Nearly 22% Today

Motley Fool

a year ago

Why Tempus AI Stock Skyrocketed Nearly 22% Today

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

BTIG Raises Personalis' Price Target to $7 From $5.50, Buy Rating Maintained

MT Newswires

a year ago

Personalis, Tempus Rally Friday on Expanded Collaboration Pact

Personalis and Tempus Announce Expanded Collaboration

Business Wire

a year ago

Personalis and Tempus Announce Expanded Collaboration

Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?

Zacks

a year ago

Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?

Personalis Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Personalis Second Quarter 2024 Earnings: Beats Expectations

MT Newswires

a year ago

Needham Adjusts Personalis' PT to $5.50 From $3.50, Keeps Buy Rating

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

a year ago

Personalis: Q2 Earnings Snapshot

Business Wire

a year ago

Personalis Reports Second Quarter 2024 Financial Results

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

GlobeNewswire

a year ago

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Business Wire

a year ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Business Wire

a year ago

Personalis to Announce Second Quarter 2024 Financial Results

Even after rising 48% this past week, Personalis (NASDAQ:PSNL) shareholders are still down 89% over the past three years

Simply Wall St.

a year ago

Even after rising 48% this past week, Personalis (NASDAQ:PSNL) shareholders are still down 89% over the past three years

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

Zacks

a year ago

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

MT Newswires

a year ago

Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

GlobeNewswire

a year ago

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Business Wire

a year ago

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Business Wire

a year ago

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

Business Wire

a year ago

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

Business Wire

a year ago

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Business Wire

a year ago

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript

Is Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a year ago

Is Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?

Personalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)

Simply Wall St.

a year ago

Personalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)

Thomson Reuters StreetEvents

a year ago

Q1 2024 Personalis Inc Earnings Call

GuruFocus.com

a year ago

Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...

Associated Press Finance

a year ago

Personalis: Q1 Earnings Snapshot

Share on Social Networks: